Table 1.
Baseline characteristics of the study population.
| FH (n = 260) | |
|---|---|
| Demographic Characteristics Age, years | 49.4 ± 6.22 |
| Men, n (%) | 129 (49.6) |
| ASCVD, n (%) | 80 (30.8) |
| Body mass index, kg/m2 | 25.3 ± 2.24 |
| FH Genotype | |
| Pathogenic variants, n (%) | 267 (100.0) |
| LDLR, n (%) | 261 (97.7) |
| ApoB, n (%) | 4 (1.5) |
| PCSK9, n (%) | 1 (0.4) |
| ApoE, n (%) | 1 (0.4) |
| FH Phenotype | |
| Heterozygous, n (%) | 254 (97.7) |
| Double heterozygous, n (%) | 3 (1.1) |
| Compound heterozygous, n (%) | 2 (0.8) |
| Homozygous, n (%) | 1 (0.4) |
| Pretreated Lipid Profile TC, mg/dL | 362.38 ± 19.48 |
| HDL-C, mg/dL | 51.38 ± 10.5 |
| TG, mg/dL | 96.5 (71.5–115.5) |
| LDL-C, mg/dL | 257.53 ± 18.15 |
| Non-HDL-C, mg/dL | 301.51 ± 19.12 |
| Risk Factors Type 2 diabetes, n (%) | 6 (2.3) |
| Hypertension, n (%) | 72 (27.7) |
| Smokers, n (%) | 59 (22.7) |
| ≥2 risk factors, n (%) | 34 (13.1) |
| Treatments | |
| High-intensity statin, n (%) | 191 (73.5) |
| Moderate-intensity statin, n (%) | 64 (24.6) |
| Low-intensity statin, n (%) | - |
| Statin intolerant, n (%) | 5 (1.9) |
| Ezetimibe, n (%) | 225 (86.5) |
| PCSK9 inhibitor, n (%) | 62 (23.8) |
| Statin plus ezetimibe, n (%) | 195 (75.0) |
| Statin plus ezetimibe plus PCSK9 inhibitor, n (%) | 57 (21.9) |
| Antiplatelet therapy, n (%) | 80 (30.8) |
Data are presented as mean ± standard deviation, percentages or median (interquartile range). FH = familial hypercholesterolemia, ASCVD = atherosclerotic cardiovascular disease, LDLR = low-density lipoprotein receptor, ApoB = apolipoprotein B, PCSK9 = proprotein convertase subtilisin-kexin type 9, ApoE = apolipoprotein E, TC = total cholesterol, HDL-C = high-density lipoprotein cholesterol, TG = triglycerides, LDL-C = low-density lipoprotein cholesterol.